Several LPAR1 antagonists have recently been evaluated in clinical trials for treating idiopathic pulmonary fibrosis and diffuse cutaneous systemic sclerosis [39, 40], considering that the LPA and LPAR1 roles have been demonstrated in animal models and patients [44, 45]. Here, LPAR1 is linked to idiopathic pulmonary fibrosis.